



For Required Non-U.S. Analyst and Conflicts Disclosures, please see Required Disclosures section at the end of each comment.

Features of the Week

Four Consumer Discretionary Themes; by Jonathan Golub, November 18

- **Consumer Is King in a Weak Recovery** - Despite weak job growth and stagnant wages, Consumer Discretionary has been the best-performing sector throughout the recovery. Importantly, these returns are the result of superior earnings, rather than a shift in sentiment. We expect bottom-line results and stock price performance for the group to outpace the market again in 2014–15.
- **Themes 1 & 2: Durables and High-End Purchases Supported by Macro Tailwinds** - Over the past four years, Consumer Durables, i.e., Autos and Homebuilders, have been big winners on the back of attractive financing rates and low base effects (these groups were decimated during the downturn). While a backup in mortgage yields has been a challenge more recently, affordability remains quite elevated. Separately, income and wealth disparities have widened since the downturn, aiding both individuals and the business that service them.
- **Themes 3 & 4: Continued Success for Media; Challenges for Brick & Mortar** - Over the past several years, changes in Media, Technology, and Telecom have been a disruptive force, shifting consumer spending patterns. This is manifesting itself in an increase in on-line purchases as well as spending on connectivity and content. This has resulted in a more challenging environment for traditional brick & mortar Retailing, as well as Restaurants and Apparel. While these groups have generally performed in line with the broad market, secular changes make them less appealing than other areas within the Consumer space.

[Four Consumer Discretionary Themes](#)

Strategic Investment Ideas

Aerie Pharmaceuticals, Inc. (AERI) - Targeting glaucoma with a new mechanism of action; by Adnan Butt, November 18

- We are initiating coverage on Aerie Pharmaceuticals with an Outperform rating and a \$20 price target. AERI is an ophthalmology focused company developing drugs for glaucoma, which affects millions of patients worldwide. We believe AERI's product candidates could demonstrate greater efficacy, safety and convenience than currently available glaucoma drugs. Clinical results expected in 2014, 2015 and 2016 could help determine the ultimate market potential of AERI's drugs and lead to value inflection opportunities as soon as mid-2014. There is potential for significant upside as both AR-13324 and PG324 use a new, first-in-class mechanism of action for the treatment of glaucoma, which is both needed by patients and potentially attractive for physicians. Given that ophthalmology remains an attractive therapeutic area, progress through clinical, regulatory and commercial milestones could all be upside catalysts.

[Targeting glaucoma with a new mechanism of action](#)



Gaming and Leisure Properties, Inc. (GLPI) - Born to Be Acquisitive; Initiating with an Outperform and \$51 PT; by John Kempf, November 22

- **GLPI is an attractively priced specialty REIT with a unique opportunity to drive significant AFFOPS growth via accretive acquisitions.** GLPI has a strong balance sheet and a stable underlying CF stream via its master-lease with Penn. We expect GLPI will diversify its cash flow with ~\$500MM of acquisitions over the next two years. In 2014, we expect GLPI will pay \$2.57/sh in distributions, implying a 5.8% yield.
- **GLPI is a REIT, not a gaming operator.** Although it owns and operates two small gaming assets, its primary objective is to lease real estate to (initially) gaming and other leisure activity companies. As a result, we believe the valuation of GLPI should focus on the quality of the lease stream, its potential to drive earnings growth via accretive acquisitions, and the company's dividend payment.
- **Stable, visible lease income.** Despite the challenging regional gaming environment, the master-lease agreement between GLPI and Penn National Gaming has been conservatively structured to insulate GLPI from some of the downside risk, while allowing some participation in the upside. Furthermore, the master lease is senior to all of Penn's current and future liabilities and is protected by cross-default language at the property level.
- **Acquisitions provide avenue for accretive growth and further diversification.** Over the next two years, we estimate GLPI will complete \$500MM worth of transactions. We estimate the discounted value of these transactions to shares of GLPI to be ~\$6.25 per share.
- **Conservative and flexible capital structure.** Following the spin-off, GLPI is well capitalized with \$2.4B of low-cost debt. The company has approximately \$700MM of availability under its revolving-credit facility that bears interest at LIBOR + 175bp. In addition, its debt is currently split rated with investment-grade (BBB- from S&P and Ba1 from Moody's) ratings on one side.

[Born to Be Acquisitive; Initiating with an Outperform and \\$51 PT](#)

ASH Planner, Expectations, What To Look For: CELG, GILD, PCYC, INFI; by Michael Yee, November 17

- **ASH (Dec 7 -10):** Symposia are Friday but key datasets are Sat-Mon and key analyst events (CELG, PCYC, INFI) are Sun-Mon. Clinical updates are the key focus this year (CELG's MM-020, GILD's PHIII R/R CLL and many midcap updates INFI, GERN, KPTI, ONTX, AMBI) but commercial outlook for launches of targeted orals (PCYC, GILD) for leukemia is also center stage **Contact us for a copy of our ASH Planner with events and key data times**
- Inside we present a guide for investors of the key classes of compounds for the diseases that we think matter this year at ASH and a table of over 50 drugs and key presentations to follow.

[ASH Planner, Expectations, What To Look For: CELG, GILD, PCYC, INFI](#)

RBC Compass; 2014 North American Railroad Shipper Survey by Walter Spracklin, November 21

- **Survey taps into the sentiment of the railroads' top customers.** We are pleased to present the findings of our 2014 Shipper Survey. Key findings of our study focus on shippers' expectations for 2014 regarding: the direction of rail rates; volume growth; and service performance. In addition, we have added a set of questions this year to get shippers' perspective on the impact of recent management changes at CNR and CP.
- **Pricing gains to moderate, yet remain positive in 2014.** The largest group of respondents (42%) anticipate +1%-3% pricing growth, which is consistent with our yield assumptions of +1.4%-3.5% for the Class 1 railroads next year. We consider survey findings on price to have neutral implications for rail shares.
- **Shippers' volume outlook is improving.** Shippers' volume expectations once again converged on flat to modest growth (+1%-5%) as 68% aligned with this view; however the proportion of respondents forecasting significant volume growth (5%+) increased to 26% for 2014 (up from 15% for 2013). We see risk to the upside on anticipated freight volumes next year.
- **Shipper sentiment on rail service remains positive.** Shippers' perception of freight rail service has moderated this year, nonetheless a strong majority (64%) continue to rate the Class 1 railroads' service offering as "Good" or "Excellent". In our view, current sentiment supports steady rate increases for the foreseeable future.

[RBC Compass](#)



Sensors: Thinking About ST Implication Given Recent Moves By APH and TEL.; APH Acquires GE's Sensor Business, TEL Showcases \$200M Sensor Asset. by Amit Daryanani, November 19

- **RBC Perspective:** We have fielded increasing numbers of questions from investors this week regarding implications to the sensor industry post recent acquisition by Amphenol (acquired GE's Sensor business) and TEL's comments at its analyst day about growth ambitions in sensors. We don't think APH and TEL entering the sensor market is a negative for ST, rather it's a validation of ST's core markets and the attractive content growth story. However, it does raise investor concerns around a) lack of deals at ST, and b) does increased competition create risks to the margin profile of ST?

[Sensors: Thinking About ST Implication Given Recent Moves By APH and TEL.](#)

Top Tactical Trades

Yum! Brands, Inc. (YUM) - New segmentation today, higher growth and valuation tomorrow?; by David Palmer, November 21

- [We believe Yum's new segment reporting will serve to bolster growth by enabling the sharing of each brand's best practices across geographies. We also believe the new structure will challenge investors to appropriately value each of the segments relative to their global peers.](#)
- **How will this help or hurt growth?** One of the advantages of a global company is the sharing of best practices. In the past, it seemed that the US struggled with this sharing across brands. Can KFC US and Pizza Hut US gain insights and inspiration from their global market peers (and visa versa)? Can Pizza Hut International narrow the growth gap to Dominos now that it is the "growth vehicle" of the new global Pizza Hut?
- **How will investors value each of Yum Brands' new parts?** For instance, is Taco Bell worthy of a Wendy's EV/EBITDA multiple (which is 12x EV/EBITDA)? Is global KFC worthy of a Burger King multiple (which is 13.5x EV/EBITDA)? Will a global Pizza Hut be worthy of a Domino's multiple (14x EV/EBITDA)? These multiples imply that Yum Brands' non-China businesses could be valued at more than 13x EV/EBITDA.
- **What will the new Yum! look like?** We estimate that the new KFC, Pizza Hut, and Taco Bell segments will represent 22%, 19%, and 17% of global profit, respectively, with China accounting for the remaining 42% (see Exhibit 2).
- **Is one of these division presidents the next CEO?** With this change, David Novak has added three direct reports, each managing a substantial slice of the global Yum empire.
- **YUM is rated Outperform with an \$80 price target:** Our price target is based on two methods: 1) DCF analysis, which yields an \$80 value based upon a terminal growth rate of 1.6% and a WACC of 8.7%; and 2) a sum-of-the-parts analysis.

[New segmentation today, higher growth and valuation tomorrow?](#)

Rayonier, Inc. (RYN) - Dissolving Doubts – Time to Step In; by Paul Quinn, November 18

- [Upgrading to Outperform \(from Sector Perform\) with ~23% potential upside to our \\$52 12-month price target as we have become more comfortable with likely specialty dissolving pulp \(CS\) prices in 2014. Acetate pulp demand \(primarily for cigarette filter\) appears stable and supply risks seem overblown. Additionally, we see the potential for meaningful earnings surprise \(to the upside\) over 2014/15 from the Real Estate \(HBU\) business.](#)
- **With the stock down 25.0% since the Q3 call on October 24 (vs. 2.5% increase in the S&P500), we believe current valuation offers an attractive entry point.** While we could always look past the longer transition that RYN will have for the Jesup C-mill into CS (2017/18 now versus 2016 before), and RYN can get around the great tariff wall in China (21.7%) for its new viscose volumes by [producing fluff again](#) if need be, the magnitude of price declines for CS in 2014 had been our biggest concern holding us back at Sector Perform until now. After much discussion with several of our trade sources, we remain comfortable with the estimate we made post-Q3 results that RYN's CS prices will decline 5% y/y (-\$95/tonne) in 2014.

[Dissolving Doubts – Time to Step In](#)



Macro Musings

Rotation to Financial and Discretionary laggards; by Robert Sluymer, November 18

- The current technical backdrop remains positive with more evidence of a supportive rotation taking hold within the equity market. Examples below include MET, BAC, JPM, HD, GM, WYN, LAMR and MON.
- The list of negatives listed in today's note (sentiment, VIX, etc.) remain legitimate concerns but we would need to see evidence that negative momentum and relative performance divergences are in place to conclude a correction is developing.
- At the equity index level a break below last week's lows would likely be required to create more concerning divergences while relative uptrend reversals by leadership sectors (Discretionary, Industrials, Healthcare or Financials) and stocks to bonds would be needed to conclude a correction is developing.

[Rotation to Financial and Discretionary laggards](#)

Q-Tips: Highlighting Quantitative Themes; by Ronald Dottin, November 22

- **We Believe the Cost/Productivity Side of Margins Remains Under-Appreciated.** S&P 500 companies spent nearly \$600 billion on capital expenditures in 2012. It's unlikely that the full benefit of this spend has flowed through to earnings. The return on previous capex spend could contribute roughly 4–8% of 2014's profits—a primary reason that we're sticking with our increasing margins factor.
- **Margins & Sales Growth – An Attractive Tactical Idea for 1H14.** Seasonally, sales growth becomes the main focal point of investors as we enter a new calendar year. Investors' interest in it will likely increase beyond normal levels given the expectation of a global pick-up in economic activity. We believe that adding the “under-appreciated” theme of increasing margins should further boost the alpha generation of this portfolio. Please see Exhibit 3 for the current list of names.

[Q-Tips: Highlighting Quantitative Themes](#)



Upcoming Conference

Silver Conference
December 10, 2013
New York, NY

Canadian Bank CEO Conference
January 14, 2014
Toronto

Global Healthcare Conference
February 25 - 26,
New York, NY

Non-Deal Roadshows

Covidien Plc (COV)
Europe
November 24 - 27, 2013

Find our Research at:

RBC CM: www.rbcinsight.com or using our iPad App "RBC Research"
Thomson: www.thomsononeanalytics.com
Reuters: www.knowledge.reuters.com
Bloomberg: **RBCR GO**
TheMarkets.com: www.themarkets.com
Capital IQ: www.capitaliq.com





The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P") and is licensed for use by RBC. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.



Disclaimer

RBC Capital Markets is the business name used by certain branches and subsidiaries of the Royal Bank of Canada, including RBC Dominion Securities Inc., RBC Capital Markets, LLC, RBC Europe Limited, RBC Capital Markets (Hong Kong) Limited, Royal Bank of Canada, Hong Kong Branch and Royal Bank of Canada, Sydney Branch. The information contained in this report has been compiled by RBC Capital Markets from sources believed to be reliable, but no representation or warranty, express or implied, is made by Royal Bank of Canada, RBC Capital Markets, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute RBC Capital Markets' judgement as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice. This material is prepared for general circulation to clients and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. RBC Capital Markets research analyst compensation is based in part on the overall profitability of RBC Capital Markets, which includes profits attributable to investment banking revenues. Every province in Canada, state in the U.S., and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. RBC Capital Markets may be restricted from publishing research reports, from time to time, due to regulatory restrictions and/or internal compliance policies. If this is the case, the latest published research reports available to clients may not reflect recent material changes in the applicable industry and/or applicable subject companies. RBC Capital Markets research reports are current only as of the date set forth on the research reports. This report is not, and under no circumstances should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. To the full extent permitted by law neither RBC Capital Markets nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior consent of RBC Capital Markets.

Additional information is available on request.

To U.S. Residents:

This publication has been approved by RBC Capital Markets, LLC (member FINRA, NYSE, SIPC), which is a U.S. registered broker-dealer and which accepts responsibility for this report and its dissemination in the United States. Any U.S. recipient of this report that is not a registered broker-dealer or a bank acting in a broker or dealer capacity and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, should contact and place orders with RBC Capital Markets, LLC.

To Canadian Residents:

This publication has been approved by RBC Dominion Securities Inc. (member IIROC). Any Canadian recipient of this report that is not a Designated Institution in Ontario, an Accredited Investor in British Columbia or Alberta or a Sophisticated Purchaser in Quebec (or similar permitted purchaser in any other province) and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report should contact and place orders with RBC Dominion Securities Inc., which, without in any way limiting the foregoing, accepts responsibility for this report and its dissemination in Canada.

To U.K. Residents:

This publication has been approved by RBC Europe Limited ('RBCEL') which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ('FCA') and the Prudential Regulation Authority, in connection with its distribution in the United Kingdom. This material is not for general distribution in the United Kingdom to retail clients, as defined under the rules of the FCA. However, targeted distribution may be made to selected retail clients of RBC and its affiliates. RBCEL accepts responsibility for this report and its dissemination in the United Kingdom.

To Persons Receiving This Advice in Australia:

This material has been distributed in Australia by Royal Bank of Canada - Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product and consider that document before making any decision about whether to acquire the product. This research report is not for retail investors as defined in section 761G of the Corporations Act.

To Hong Kong Residents:

This publication is distributed in Hong Kong by RBC Investment Services (Asia) Limited, RBC Investment Management (Asia) Limited and RBC Capital Markets (Hong Kong) Limited, licensed corporations under the Securities and Futures Ordinance or, by the Royal Bank of Canada, Hong Kong Branch, a registered institution under the Securities and Futures Ordinance. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact RBC Investment Services (Asia) Limited, RBC Investment Management (Asia) Limited, RBC Capital Markets (Hong Kong) Limited or Royal Bank of Canada, Hong Kong Branch at 17/Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (telephone number is 2848-1388).

To Singapore Residents:

This publication is distributed in Singapore by the Royal Bank of Canada, Singapore Branch and Royal Bank of Canada (Asia) Limited, registered entities granted offshore bank and merchant bank status by the Monetary Authority of Singapore, respectively. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. You are advised to seek independent advice from a financial adviser before purchasing any product. If you do not obtain independent advice, you should consider whether the product is suitable for you. Past performance is



not indicative of future performance. If you have any questions related to this publication, please contact the Royal Bank of Canada, Singapore Branch or Royal Bank of Canada (Asia) Limited.

To Japanese Residents:

Unless otherwise exempted by Japanese law, this publication is distributed in Japan by or through RBC Capital Markets (Japan) Ltd., a registered type one financial instruments firm and/or Royal Bank of Canada, Tokyo Branch, a licensed foreign bank.

® Registered trademark of Royal Bank of Canada. RBC Capital Markets is a trademark of Royal Bank of Canada. Used under license.

Copyright © RBC Capital Markets, LLC 2013 - Member SIPC

Copyright © RBC Dominion Securities Inc. 2013 - Member CIPF

Copyright © RBC Europe Limited 2013

Copyright © Royal Bank of Canada 2013

All rights reserved